The European Medicines Agency has appealed against a court order preventing it from releasing documents relating to two marketed medicines, arguing that the disclosures are consistent with its policy on transparency.
The Food and Drug Administration has approved a new device for people with Type 1 diabetes – the first to automatically monitor blood glucose levels and release insulin at the appropriate dose. The so-called ‘artificial pancreas’ is intended to adjust insulin levels in the blood with little or no input from the user.
Evotec AG and C4X Discovery Holdings Plc have upgraded their research agreement to cover a broad range of targets for small molecule drugs. The initial focus will be on cancer and autoimmune diseases.
The Phacilitate conference on cell and gene therapy in Berlin on 21 to 22 September produced more uplifting statistics about how the new regenerative technologies are enabling patients with refractory disease to gain a new lease on life.
Adaptimmune Therapeutics Plc and the MD Anderson Cancer Center of the University of Texas have agreed to cooperate on T-cell receptor technology for treating solid and blood cancers.
GlaxoSmithKline Plc has named Emma Walmsley, currently head of the company’s consumer healthcare division, as the successor to Andrew Witty, the chief executive officer. Mr Witty will be retiring on 31 March 2017.
Rejecting the advice of its advisory committee, the Food and Drug Administration has approved the first drug for Duchenne muscular dystrophy, a rare disorder that causes a progressive deterioration in the muscles of people with a specific gene mutation.
The European Medicines Agency has recommended two new cancer drugs for marketing authorisation in the European Union, one of which is for the treatment of breast cancer and the other for soft tissue sarcoma.
A UK start-up company called GammaDelta Therapeutics Ltd has joined a small number of European companies that are exploring the potential of gamma delta T cells as the basis for new immunotherapies for cancer.